Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • Bone Marrow & Stem Cell Transplant
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Targeted Therapy
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • Bone Marrow & Stem Cell Transplant
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Targeted Therapy
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Medicus Pharma Ltd Announces a Definitive Agreement to Acquire Antev Ltd. UK

July 1, 2025

Revolution Medicines and Royalty Pharma to Support Global Development and Commercialization of RAS(ON) Inhibitor Portfolio for RAS-Addicted Cancers

July 1, 2025

Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

July 1, 2025

Xcell Biosciences and Thermo Fisher Scientific to Advance the Next Generation of Cell Therapies

July 1, 2025

SunRock Biopharma and Escugen to Develop First-in-Class CCR9-Targeted ADC

June 25, 2025

Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers

June 25, 2025

Synfini Inc. and O2nix Bio to Develop Novel Cancer Therapeutics Targeting FTSJ1

June 24, 2025

Orion and Glykos announce the extension of research collaboration and licensing agreement for the development of next-gen ADCs

June 24, 2025

Marker Therapeutics and Cellipont Bioservices to Advance cGMP Manufacturing of MT-601 for Patients with Lymphoma

June 24, 2025

Teva and Fosun Pharma to Develop TEV-56278 in Immuno-Oncology

June 24, 2025

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel ADC Targeting CDH6

June 24, 2025

Enterome raises $19M to fund clinical development of OncoMimics™ immunotherapy to treat Follicular Lymphoma

June 24, 2025

MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies

June 24, 2025

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3 to RayzeBio, a BMS Company, for a potential value of up to $1.35B plus royalties

June 17, 2025

NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel CDH6-targeting ADC

June 17, 2025

Antares Therapeutics Launches with $177 Million to Develop First-in-Class Precision Medicines for Cancer and Other Serious Diseases

June 17, 2025

Enterome raises $19 million to fund clinical development of OncoMimics™ immunotherapy to treat Follicular Lymphoma

June 17, 2025

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

June 17, 2025

Caris Life Sciences Announces Launch of Initial Public Offering

June 17, 2025

Citius Oncology Enters into Distribution Services Agreement with Cardinal Health

June 17, 2025

BioNTech Announces Strategic Transaction to Acquire CureVac

June 17, 2025

Debiopharm And Alkyon Therapeutics Announce Research Collaboration To Advance The Next Generation Of Radioligand Therapies

June 17, 2025

AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research

June 17, 2025

Elevation Oncology Enters into Agreement to Be Acquired by Concentra Biosciences

June 11, 2025

Vividion Therapeutics and Bayer Partnership Aims to Further Strengthen Oncology Pipeline With Solid Tumor Inhibitor

June 11, 2025
Page1 … Page12 Page13 Page14 Page15 Page16 … Page42

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.